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Metal ion mediated transition from random coil to
b-sheet and aggregation of Bri2-23, a natural
inhibitor of Ab aggregation†
Marek Luczkowski,*a Riccardo De Ricco,*b Monika Stachura,c Slawomir Potocki,a
Lars Hemmingsenc and Daniela Valensin*b
Furin-dependent maturation of the BRI2 protein generates the Bri2-23 fragment that is able to arrest the
aggregation of amyloidb, the peptide implicated in Alzheimer’s disease (AD). Bri2-23 contains cysteines
at positions 5 and 22, which are likely to bind to metal ions such as Cu(I). Metal ions may play a role in
the etiology of neurodegenerative disorders such as AD, and in this work we explore the metal ion
induced folding and aggregation of Bri2-23 using Hg(II) and Ag(I) as spectroscopic probes with structural
and ligand preferences similar to those of Cu(I), while not displaying redox activity under the
experimental conditions. In general, interaction of Bri2-23 with soft metal ions changes the structural
properties and solution behavior of the peptide that tune to increasing metal to peptide stoichiometry.
Potentiometric, 199mHg PAC and ESI-MS data indicate that addition of up to 0.5 equivalents of Hg(II) to
Bri2-23 yields a two-coordinated HgS2 structure at the metal site. While the free peptide is inherently
unstructured, the presence of Ag(I) and Hg(II) gives rise to b-sheet formation. NMR spectroscopy
supports the formation of b-sheet structure in the presence of 0.5 equivalents of Hg(II), and displays
an interesting and marked change in the TOCSY spectra when increasing the Hg(II) to peptide
stoichiometry from 0.5 to 0.7 equivalents, indicating the equilibrium between two structural analogues
of the complex. Addition of more than 0.7 equivalents of Hg(II) gives rise to line broadening, presumably
reflecting aggregation. This is further supported by ThT fluorescence studies showing that the Bri2-23
peptide does not aggregate over 24 hours, while addition of over 0.7 equivalents of Ag(I) or Hg(II) leads
to increase of fluorescence, indicating that these metal ions induce aggregation. Thus, a model integrating
all data into a coherent picture is that the metal ion binding to the two thiolates gives rise to folding of the
peptide into a structure that is prone to aggregation, forming aggregates with a considerable amount of
b-sheets. Molecular dynamics simulations initiated with structures that agree with NMR data additionally
support this model.
Introduction
BRI2, also known as ITM2b, is a type II transmembrane protein
with unknown function abundantly expressed in neuronal
tissues. It is 266 amino acids long and can be divided into a
large C-terminal extracellular domain, a transmembrane domain,
and a short N-terminal cytoplasmic domain. Mutations of the
ITM2b gene result in the expression of the protein precursors
ABriPP and ADanPP.1 Like the amyloid precursor protein (APP),
BRI2 is subject to enzymatic processing by a number of proteolytic
a Faculty of Chemistry, University of Wroclaw, F. Joliot Curie 14, 50-383 Wroclaw, Poland. E-mail: marek.luczkowski@chem.uni.wroc.pl
b Department of Biotechnology Chemistry and Pharmacy University of Siena, Via A. Moro, 53100 Siena, Italy. E-mail: daniela.valensin@unisi.it
c Department of Chemistry, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
† Electronic supplementary information (ESI) available: Mass spectrometry analysis of the ternary system; Fig. 1S, ESI-MS spectra of the Hg(II) complex of the Bri2-23
peptide at pH 11 in ammonium hydroxide (0.4 M). cBri2-23 = 1  104 M; Hg(II)/Bri2-23/Cys ratio 1 : 1 : 1; MeOH/H2O = 1 : 2. Fig. 2S, the isotopic profile of ternary Hg(II)
complex species of Bri2-23 and cysteine at pH 11 in ammonium hydroxide (0.4 M). [Bri2-23] 1  104 M; Hg(II)/Bri2-23/Cys ratio 1 : 1 : 1; MeOH/H2O = 1 : 2; isothermal
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enzymes, including prohormone furin-like convertases able to
cleave the WT BRI2 protein near the C-terminus to produce a
23-amino acid peptide, called Bri2-23 (Fig. 1). Similarly to WT
BRI2, ABriPP and ADanPP proteins also undergo proteolytic
cleavage at the C-terminal region generating ABri and ADan
peptides (Fig. 1).2,3 These peptides constitute the hallmarks
of the Familiar British Dementia (FBD) and Familiar Danish
Dementia (FDD) disorders, that share many mechanistic and
pathological similarities with Alzheimer’s disease (AD).1 This
process is initialized by the activation of the convertase in
the trans region of the Golgi apparatus and continues once the
secretory vesicle merges with the cellular membrane. Although
both the Golgi lumen and extracellular space represent the
exoplasmic face of the membrane, they diﬀer in redox potential,
with the lumen being a more reductive environment.4,5
The accumulation of ABri and ADan triggers a complex
pathological cascade of events leading to neurodegeneration,6,7
while Bri2-23 preserves its solubility.8 Both ABri and ADan
peptides exist in reduced or oxidized form due to the presence
of two cysteine residues within the peptide sequence, which are
able to form disulphide bridges.9 However, the consequences of
the oxidation are found to be contradictory with respect to the
peptides’ susceptibility to form oligomers and to aggregate.10
While the intramolecular disulphide bridge promotes the b sheet
formation and aggregation with subsequent fibrillation in ABri,11
the amyloid-like aggregates of ADan are mainly formed by the
reduced form of the peptide.10 These contradictory results imply
that the upstream formation of non-fibrillar soluble oligomers
rather than insoluble aggregates representing the pathogenic
species causes neurodegeneration.10,12
Contrary to the ABri and ADan behavior, the wild type peptide,
Bri2-23 has no toxic eﬀects, yielding neither oligomers nor aggre-
gates of high order. Interestingly, Bri2-23 has been found to inhibit
Ab aggregation in vitro and in vivo.13 This inhibitory eﬀect is probably
mediated by the fragment containing the –FENKF– sequence, which
is analogous to that found in peptidic inhibitors of amyloid
aggregation (–KLVFF–).14 Moreover, a peptide encompassing
similar sequence has been demonstrated to interact with the
glycine-zipper segment of Ab1–40 (–G33XXXG37–) that is critical
for the formation of a stable b sheet structure.14,15 In addition,
the Bri2-23 peptide transported to the plasmamembrane, is able
to interact with APP reducing the access of a-, b- and g-secretases
to their respective cleavage sites.16 As a result, the release of any
APP metabolite, including Ab, is reduced.
Transition metal ions, like Cu, Zn and Fe are implicated
in many neurodegenerative disorders and are believed to influ-
ence either the aggregation of amyloidogenic proteins or the
formation of reactive oxygen species (ROS).17–28 Metal ions are
involved in the aggregation of ABri and ADan peptides as well.20
On the other hand nothing is known about the metal binding
abilities of Bri2-23 and more importantly whether metal ions
affect its structure and aggregation ability. Bri2-23 contains
several residues, like Cys, His, Glu (Fig. 1), which might interact
with metal transition ions. In particular, the presence of two
cysteines points out a possible Cu(I)–S2 coordination geometry
and high Cu(I)–Bri2-23 affinity.
Herein, we aim at investigating the interaction between
Cu(I) and Bri2-23 by combining experimental and theoretical
methods. In order to elucidate the role, if any, played by the
cuprous ion we used Hg(II) or Ag(I), as spectroscopic probes of
Cu(I),29 while Molecular Dynamics calculations (MD) were
performed by using Cu(I). The choice to use Hg(II) and Ag(I)
as Cu(I) probes was due to the fact that Cu(I) is a redox active
metal which can easily oxidize to Cu(II). For this reason sample
preparation is usually performed in inert atmosphere and in
the presence of reducing agents such as ascorbic acid or
dithionite. Unfortunately, such a procedure does not comple-
tely exclude the presence of Cu(II), which although very small
can interfere with Cu(I)–Bri2-23 binding in two different ways:
(i) by interacting with the peptide and (ii) by oxidizing Cys
residues. Moreover, Hg(II) and Ag(I) ions are commonly used to
investigate Cu(I) sites, as demonstrated by previous studies.30–41
By applying a multitechnique approach we characterize the metal
coordination sphere, the binding affinity and stoichiometry, the
speciation profiles and the structural rearrangements of Bri2-23
induced by the metal ion.
Experimental section
Peptide synthesis and purification
Peptides were synthesized on an Activotec Activo-P11 automated
peptide synthesizer, on a 0.25 mmol scale using standard Fmoc
chemistry.42 Fmoc–Ser(tBu)–Wang resin was used as the solid
support so that the resulting peptides would have a unprotected
C-terminus as in the natural system. Cleavage from the resin was
performed for 120 min in a 90% trifluoroethanol (TFA) solution
containing 5% thioanisole, 2% anisole, and 3% ethanedithiol as
free radical scavengers. After precipitation with cold ether, the
peptides were redissolved in water and lyophilized to obtain a
fluffy off-white powder. The solid was redissolved in 10% acetic
acid and purified by reversed phase HPLC on a Varian Prostar
HPLC with a preparative C18 column (Varian Pursuit XRs C 18)
Fig. 1 Schematic representation of Bri2 protein, its disease related forms
and the products of their enzymatic processing by furin.
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with a semi-linear gradient of 0.1% TFA in water to 0.1% TFA in
9 : 1 CH3CN/H2O over 45 min. The identity of the peptides was
verified by ESI (electrospray ionization) mass spectrometry.
ThT fluorescence spectroscopy assay
The fluorometric assay was performed on a FP-6500 JASCO
spectrofluorometer. The peptide Bri2-23 was analyzed in the
presence and in the absence of 0.7 equivalents of Ag(I) and
Hg(II). 50 mM phosphate buﬀer solutions (pH 7.4) were used to
dissolve the peptide to a final concentration of 10 mM. Thioflavin-T
was added to all analyzed systems to give a 10 mM final concen-
tration. All the samples were monitored immediately after the
preparation and after one day of incubation at room temperature.
Mass spectrometry
High-resolution mass spectra were obtained on a BrukerQ-FTMS
spectrometer equipped with an Apollo II electrospray ionization
source with an ion funnel. The mass spectrometer was operated in
the positive ion mode with the following parameters: scan range
m/z 400–1600, dry gas-nitrogen, temperature 170 1C, ion energy
5 eV. Capillary voltage was optimized to 4500 V to obtain the
highest S/N ratio. Changing the voltage (500 V) did not
significantly affect the optimized spectra. The samples (metal/
ligand in a 1 : 1 stoichiometry, cBri2-23 = 1  104 M) were
prepared in a 9 : 9 : 2 MeOH/H2O/DMSO mixture in carbonate
buffer pH 6.5. Variation of the solvent composition down to 5%
of MeOH did not change the speciation. The sample was
infused at a flow-rate of 3 mL min1. The instrument was
calibrated externally with the Tunemixtmixture (Bruker Daltonik,
Germany) in quadratic regression mode. Data were processed
by using the Bruker Compass Data Analysis 4.0 program. The
mass accuracy for the calibration was higher than 5 ppm,
enabling together with the true isotopic pattern (SigmaFit) an
unambiguous confirmation of the elemental composition of
the obtained complex.
Circular dichroism spectroscopy
CD spectra were recorded using a Jasco J-815 spectropolari-
meter and the temperature was controlled with a PTC-423S
temperature controller. A quartz cell with 1 cm optical path was
used. The spectra range was 190–260 nm with a resolution of
0.1 nm and a bandwidth of 1 nm. A scan speed of 20 nm min1
with 1 s response time was employed. Baseline spectra were
subtracted from each spectrum and data were smoothed using
the Savitzky–Golay method. Data were processed using Origin
7.0 spread sheet/graph package. The direct CD measurements
(y, in millidegrees) were converted to mean residue molar
ellipticity, using the relationship mean residue De = y/(33000 
c l number of residue). 10 mM solution of apo and metal (Ag(I)
and Hg(II)) bound Bri2-23 either in phosphate buffer (50 mM) and
at acidic pH (B3.0) were analyzed.
Potentiometry
Stability constants for protons and Hg(II) complexes of cysteine
and Bri2-23 were calculated from titration curves obtained at 298 K
using a total volume of 1.5 cm3. The metal ion concentration
was 5  104 mol dm3 and the metal to ligand ratio was
1 : 2. Competition experiments were carried out with a 5 
104 mol dm3 Bri2-23 peptide in the presence of 1 equivalent
of cysteine and 1 equivalent of Hg(II) after 1 hour of equili-
bration time was allowed before the titration started. NaOH was
added using a 0.500 cm3 micrometer syringe which was cali-
brated by both weight titration and the titration of standard
materials. The pH-metric titrations were performed at 298 K
in 0.1 mol dm3 NaCl on a MOLSPIN pH-meter system using
a Mettler Toledo InLab semi micro combined electrode calibrated
in hydrogen concentrations using HCl.43 The HYPERQUAD pro-
gram was used for stability constant calculations.44 Standard
deviations were computed by HYPERQUAD and refer to random
errors only. They are, however, a good indication of the impor-
tance of a particular species in the equilibrium.
Isothermal titration calorimetry
Calorimetric titrations of the peptide with Hg(II) ions were
performed by isothermal titration microcalorimetry (ITC) using
a Nano-ITC Instrument (Ta Instruments, USA). Experiments
were carried out at 298 K in distilled water at pH 3.0. Peptide
concentration was 0.5 mM (950 mL sample cell), while the metal
ion concentration 5.0 mM (in the syringe). Both solutions were
degassed for at least 15 min by using a TA Instruments
degassing station, and then stored under nitrogen to minimize
sample oxidation. Automated titrations were performed until
saturation, up to the Hg(II)/peptide mole ratio of about 3. The
experiment was repeated three times. Heat of dilution and
mixing for each experiment were measured by titrating Hg(II)
solution into distilled water at pH 3.5. The eﬀective heat of each
peptide metal ion interaction was corrected for dilution and
mixing eﬀects. Heats of bimolecular interactions were obtained
by integrating the peaks of each injection. The data were
analyzed using the NanoAnalyze software v. 2.3.6, using a ‘‘multi-
ple sites’’ binding model. DH1 and the corresponding binding
constant, Ka, molar free energy of binding, DG1, and the molar
entropy change, DS1, were attained from the fundamental equa-
tions of thermodynamics: DG1 = RT lnKa = DH1  T (DS1).
Perturbed angular correlation spectroscopy
The following stock solutions were prepared and used for
the PAC experiments: Bri2-23 (2 mM, concentration determined
by the Ellman’s test),45 phosphate buﬀer of pH 3.0 and pH 7.5
(0.93 M), and HgCl2 (3.0 mM). The final samples contained
50 mM of the appropriate buﬀer, 200 mM or 100 mM Bri2-23,
and 100 mM of HgCl2 in 55% sucrose. Water (150 mL) treated so
as to lower the concentration of metal ions was placed in a
small teflon cup sitting on a copper device, frozen in liquid
nitrogen and mounted at the ISOLDE GLM beam line (at CERN)
in a vacuum chamber. Radioactive 199mHg was implanted in the
ice typically for 1 hour. The radioactive 199mHg was produced by
irradiating a liquid lead target with 1 GeV protons and selected
using an on line mass separator. Detailed information regarding
sample preparation and data collection followed the protocol
described in Iranzo et al.46
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Fits were carried out with 300 points disregarding the first
10 points due to systematic errors in these, 0.05038 ns per
channel, 0.981 ns time resolution. The pH presented in the
table is the pH in the sample at 274 K.
NMR spectroscopy
NMR experiments were carried out at 14.1 T at controlled
temperature (0.1 K) on a Bruker Avance 600 MHz equipped
with a Silicon Graphics workstation. Suppression of the resi-
dual water signal was achieved by excitation sculpting, using a
selective square pulse on water 2 ms long. Proton resonance
assignment was obtained by TOCSY and NOESY experiments.
HSQC experiments were carried out with standard pulse sequences.
Spectral processing was performed on a Silicon Graphics O2 work-
station using the XWINNMR 3.6 or TOPSPIN 3.1 software. Solutions
of apo and metal (Ag(I) and Hg(II)) bound Bri2-23 0.3 mM either at
acidic (~3.0) and physiological pH were analyzed. The intensities of
NOESY cross-peaks, referenced to cross-peaks related to proton
pairs at fixed distances were converted into proton–proton distance
constraints; the constraints were used to build a pseudopotential
energy for a restrained simulated annealing (SA) calculation in
torsional angle space. In particular, we performed the calculation
with the program DYANA,47 with 300 random starting structures of
the peptide and 10000 steps of SA.
Molecular dynamics simulations
The MD simulations were performed with the GROMACS 3.3.0
software package48 using the GROMOS 96 force field49 and the
flexible SPC water model. The initial structure was immersed in
a periodic water box of triclinic shape (1.50 nm thickness) and
neutralized with a 1 CL-counterion. Electrostatic energy was
calculated using the particle mesh Ewald method.50 Cutoﬀ
distances for the calculation of the Coulomb and Van der
Waals interaction were 0.9 and 1.0 nm, respectively. After
energy minimization using a steepest decent method, the
system was subject to equilibration from 0 to 298 K and normal
pressure for 30 ps. The system was coupled to the external bath
by the Berendsen pressure and temperature coupling.51 No
positional restrain was given, only two distance restrains for
the Cys5–Cu(I) and Cys 22–Cu(I) binding (low = 1.8, up1 = 2.3,
up2 = 2.5). An average structure was refined further using a
steepest decent energy minimization. For simulating the
Cysteine–copper(I) bond, the CYS2 residue was selected instead
of the CYS residue in Gromos 43a2 force field to mimic the
oxidized form, ready for metal ion binding. Moreover Arginine
(+), Histidine (+) and Lysine (+) were considered in the proto-
nated form like in acidic pH, the total charge of the peptide
with Cu(I) ion was of 1+.
The starting point of the MD simulation analysis was the
NMR output structures obtained through the program DYANA
after integrating the NMR 2D NOESY spectra to obtain struc-
tural constrains. Seven of the best 30 DYANA structures were
randomly selected as the starting points for MD simulation.
The Cys–Me binding site was firstly minimized with the steepest
descend method to obtain the estimated distance between
copper and the cysteine sulfur. The distance restrains were
then applied as constrains for MD simulation analysis using
the correct Force Field for this type of Me-bounded cysteines
(CYS2 for gromos43a1). 100 ns of simulation was performed for
each structure to reach the RMSD convergence and it was
maintained for at least 20 ns. The seven analyzed structures
do not quickly reach the RMSD stabilization, so during the
50 ns of simulation a steepest descend energy minimization
was done every 5 ns, also because of the undefined positional
restrain given to the system and because of the intrinsic
unstructured part of the peptide.
Results
ThT fluorescence spectroscopy assay
The thioflavin-T (ThT) fluorimetric assay is widely used to underline
the presence of a stable b sheet secondary structure for peptides or
proteins.52,53 It is also known, especially for amyloidogenic peptides,
that a steady increase over time of the ThT fluorescent signal can be
correlated to the formation of precipitating complexes. In order to
compare the b sheet structural propensity of the peptide Bri2-23, the
variation of ThT fluorescence of the Bri2-23 peptide in the presence
and in the absence of Ag(I) and Hg(II) metal ions was analyzed.
Immediately after the metal additions, similar values of ThT
fluorescence were measured (Fig. 2). In contrast, the same
experiments repeated after 24 hours showed an increase of
ThT fluorescence of Bri2-23 solutions containing metal ions
only. In particular, at t = 24 hours, the apo peptide gave almost
the same ThT fluorescence as measured at t = 0, while the
binding to Ag(I) or Hg(II) ions resulted in 30–50% of fluores-
cence enhancements. This behavior supports the propensity of
the metal bound Bri2-23 peptide to form b sheet structure in
solution, and confirms that a similar structural reorganization
of the peptide is induced by Ag(I) and Hg(II).
Mass spectrometry
The results of mass spectrometric analyses indicate that at
slightly acidic pH conditions apo Bri2-23 (data not shown) and
Fig. 2 Relative fluorescence ThT intensity at 480 nmmeasured at t = 0 and
t = 24 h in 50 mM phosphate buﬀer pH 7.0 for free Bri2-23 10 mM and in the
presence of 0.7 equivalents of Ag(I) and Hg(II), respectively; cThT = 10 mM.
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its mercurated complex (m/z = 943.8 and 1415.2) exist as
monomers (Fig. 3). No species of higher ligand content with
respect to metal have been detected, but this may be because it
is diﬃcult to detect polymeric forms of ligand or its complexes.
To reduce the system’s aggregation susceptibility in the presence
of metal, the mixture used in experiments contained 10% of
DMSO. Interestingly, in the absence of DMSO (data not shown) no
spectra was obtainable for the peptide in the presence of Hg(II),
possibly indicating aggregation. The MS data can be modeled
with doubly deprotonated Bri2-23 and one Hg(II) ion bound,
presumably reflecting coordination by the two thiolates.
Circular dichroism spectroscopy
At both physiological and acidic pH apo Bri2-23 displays typical
random coil CD spectra (Fig. 4A), with the main absorption at
198 nm characteristic of flexible and disordered protein.54
Upon Hg(II) and Ag(I) addition the CD spectra undergo changes
in both the shape and in the wavelength of the main adsorption
bands (Fig. 4B and C). The two metals gave very similar changes,
showing a negative absorption at 208–210 nm. The difference
spectra (Fig. 4D) obtained by subtracting the CD spectra of the apo
peptide from the metal complexes have the typical shape of those
of b sheet proteins, thus supporting the ThT results indicating
that Bri2-23 forms a b sheet structure in the presence of both
Hg(II) and Ag(I) ions. It cannot be excluded that the CD spectro-
scopic changes originate from LMCT bands appearing upon the
binding of the metal ions to Bri2-23. However, the change towards
a b sheet like spectrum upon metal ion binding is remarkable,
and appears qualitatively similar for both metal ions.
Potentiometric studies
Potentiometric titration reflects that in the measured pH
range the unprotected EASNCFAIRHFENKFAVETLICS peptide
(Bri2-23) behaves like H9L acid (Table 1). The nine protonation
constants correspond to consecutive proton binding to the
e-amino group of Lys, thiolate groups of two Cys, the terminal
a-amino group, imidazole nitrogen of His, g-carboxylate of
three glutamate residues and the terminal a-carboxylate group.
Fig. 3 ESI-MS spectra of the Hg(II) complex of the Bri2-23 peptide at
pH 6.5 in carbonate buﬀer (1 mM). cBri2-23 = 1  104 M; Hg(II)/Bri2-23 ratio
1 : 1; MeOH/H2O/DMSO = 9 : 9 : 2.
Fig. 4 CD spectra recorded at pH 2.5 (3 mM HCl) and 7.0 (50 mM phosphate buﬀer) for 10 mM apo Bri2-23 (A), 10 mM Bri2-23 in presence of
1.0 equivalent of Ag(I) (B); 10 mM Bri2-23 in presence of 1.0 equivalent of Hg(II) (C) and diﬀerence CD spectra for mercurated peptide and its apo form (D).
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The protonation of the guanidinyl function of the Arg residue
cannot be followed.
Since mercury(II) is known for its extreme high aﬃnity to
sulfhydryl-containing ligands,55,56 the reasonable explanation
of the interactions between the Bri2-23 ligand and Hg(II)
obligate us to emphasize that the total complexation of the
metal ion with this ligand is essentially complete below pH 2.
Therefore, complex formation constants could not be deter-
mined directly from potentiometric titration and competitive
potentiometric experiments were carried out with cysteine as a
competitor ligand under our experimental conditions.57 First,
the protonation constants for cysteine were determined from
potentiometric titrations followed by the determination of
stability constants for its mercuric complexes where the for-
mation constant reported by Stricks and Kolthoﬀ for Hg(Cys)2
species was used as the fixed value.55 Constants determined for
cysteine can be assigned to amine (10.21), thiolate (8.24) and
carboxylate (2.12) protonations (Table 1). As in previous stu-
dies57 five complex species have been found within the mea-
sured pH range all engaging two ligands in Hg(II) sequestration
(Table 2). Subsequently, potentiometric titration at a 1 : 1 : 1
Hg(II)/Cys/Bri2-23 ratio was carried out. Slow stabilization in the
competition region resulted in relatively high standard devia-
tions reported for the calculated complex species. The best
fit results are presented in Table 2. Comprehensive analysis
of potentiometric data reveals the presence of 13 complex
species, five (HgH3Cys2, HgH2Cys2, HgHCys2, HgCys2, HgH1Cys2)
representing binary Hg(II) species of cysteine, five binary com-
plexes of mercury(II) bound Bri2-23 (HgH6L, HgH5Bri, HgH4Bri,
HgH3Bri, HgH2Bri) and three ternary complex species (HgH2CysL,
HgHCysL, HgCysL) that coexist in the alkaline pH range (Fig. 5).
Although Bri2-23 is a moderately weak competitor of
cysteine, we are able to determine the stability of its mercuric
complexes in the ternary system. Usually, the most reliable mea-
sure that allows for direct assessment of aﬃnity of various ligands
toward metal ions is logK*, the protonation corrected stability
constant.58 Taking into account the relatively high standard devia-
tion we are able to quantify the logK* for Bri2–23 Hg(II) complexes
to vary between 0.5 and 2. This discrepancy is the consequence of
structural rearrangements of the peptide chain that mutually result
from metal binding and changes in proton concentration. Exten-
sions of the peptide sequence with a structure-rearranging domain
usually increase the stability of its metal complexes.59,60 The analo-
gous estimate of logK* for cysteine complexes of the general formula
HgHxCys2 gives a value exceeding 23. In consequence Bri2-23 could
hardly compete with cysteine for Hg(II) binding. Furthermore, if this
measure is the critical factor, such a high difference in stability
would abolish formation of ternary complexes that have been
determined by potentiometric titrations. Against all odds, mass
spectrometric analysis confirms the occurrence of ternary com-
plexes in the alkaline pH range (see Fig. 1S and 2S for details, ESI†).
The experiments performed in the ternary system have been
followed by corresponding titrations carried out for the binary
Table 1 Protonation constants for the 1 mM Bri2-23 peptide and cysteine
at T = 298.2 K and I = 0.1 M in NaCl; cBri2-23 = 1  103, cCys = 1  103
Species log b logK Residue
Bri2-23
HL 10.05(2) 10.05 Lys
H2L 19.48(2) 9.43 Cys
H3L 28.04(3) 8.57 Cys
H4L 35.62(1) 7.58 aNH2
H5L 41.98(5) 6.36 His
H6L 46.74(6) 4.76 Glu
H7L 50.87(7) 4.13 Glu
H8L 54.37(7) 3.50 Glu
H9L 57.38(9) 3.01 aCOO–
Cysteine
HL 10.21(1) 10.21 aNH2
H2L 18.45(1) 8.24 SH
H3L 20.57(1) 2.12 aCOO–
Table 2 Stability constants for the Hg(II) complexes of cysteine, Bri2-23 and
their ternary complexes at Hg(II)/Bri2-23/cysteine ratio 1 : 1 : 1; T = 298.2 K and
I = 0.1 M in NaCl; cBri2-23 = 5  104, cCys = 5  104, cHg(II) = 5  104
Speciesa log b logK logK*b
HgH3Cys2 62.51(1)
HgH2Cys2 60.04(1) 2.47
HgH1Cys2 52.44(1) 7.60
HgH0Cys2 43.57
c 8.87
HgH-1Cys2 33.51(1) 10.06
HgH6L 54.86(12) 0.49
HgH5L 51.97(11) 2.89 1.10
HgH4L 48.55(12) 3.42 1.81
HgH3L 43.91(11) 4.64 1.94
HgH2L 37.72(12) 6.19 2.10
HgH2CysL 52.85(6)
HgHCysL 43.92(6) 8.93
HgCysL 34.10(6) 9.82
a L indicates the Bri2-23 peptide as a ligand. b logK* = log b(CuHjL) 
log b(HnL) (where the index j corresponds to the number of the protons
in the coordinated ligand to the metal ion and n corresponds to the
number of protons coordinated to the ligand). c Data adapted from
Stricks and Kolthoﬀ.55
Fig. 5 Species distribution diagram for Hg(II) complexes of the Bri2-23
peptide in the presence of Cys at a 1 : 1 : 1 Hg/Bri2-23/Cys ratio; T = 298.2 K
and I = 0.1 M in NaCl; cBri2-23 = 5  104, cCys = 5  104, cHg(II) = 5  104.
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system with the aim of testing the system’s behavior in the
absence of any competing ligand. As we know from competition
experiments, Bri2-23 is hardly able to compete with cysteine for
metal binding in a wide pH range. To reproduce the constraints
of the ternary system and to keep the homogeneity of the
complex species formed in solution (vide supra) metal pool
accessible for Bri2-23 sequestration was kept at a half the
concentration of the ligand. Moreover, the formation constant
calculated for the HgH2BRI complex was used as the predeter-
mined value. The best fit results are shown in Table 3. Analysis
of potentiometric data reveal the formation of seven complex
species HgH6L, HgH5L, HgH4L, HgH3L, HgH2L, HgHL and HgL
(Fig. 6). Stability constants for corresponding complex species
formed in acidic and neutral pH range correlate well with
values calculated for the ternary system (Table 2), while for-
mation constants for species HgHL and HgL, present in the
alkaline pH range give reasonable logK* values. In addition,
available potentiometric, mass spectrometric and NMR data do
not indicate formation of complex species with two ligand
molecules binding Hg(II) (Fig. 6).
Isothermal titration calorimetry
As we know from potentiometric experiments the total com-
plexation of the metal ion with Bri2-23 is essentially complete
below pH 2 and subsequent complex species diﬀer only in the
protonation state of groups not involved in Hg(II) binding.
Therefore, comprehensive thermodynamic analysis of the inter-
action of Bri2-23 with Hg(II) by the isothermal titration calori-
metry experiments have been performed in the acidic pH range
(see ESI† for details).
Perturbed angular correlation spectroscopy (PAC)
199mHg PAC spectroscopy was conducted in order to elucidate
the metal site coordination geometry. The PAC parameters
derived from analysis of the experimental data, Fig. 4S and 7,
are summarized in Table 1S (ESI†). With a peptide :Hg(II)
stoichiometry of 2 : 1 at pH 3.0 one nuclear quadrupole inter-
action (NQI) dominates the spectra. This NQI compares well
with previous observations of HgS2 coordination geometries.
46
The same NQI is dominating at peptide :Hg(II) stoichiometry of
1 : 1 at pH 3.0. At pH 7.4 the signal is still dominated by that of
the HgS2 coordination geometry, but it changes slightly, with
line broadening especially of the second peak atB2.7 rad ns1,
and a minor decrease in frequency. The line broadening
implies either internal dynamics at the metal site or that more
than one NQI, and thus more than one coordination geometry,
is present. Thus, a second NQI was introduced in the data
analysis, see Table 1S (ESI†), and the fitted parameters fall
in-between reference data for HgS2 and HgS3 model systems,
and might indicate that a fraction of the Hg(II) ions are in
coordination geometries with a coordination number higher
than 2.46 The analysis is diﬃcult, and other fits of equal quality
may exist.
Nuclear magnetic resonance spectroscopy
In order to characterize the metal coordination sphere of
Bri2-23 and to better understand the conformational rearrange-
ments of the peptide, the NMR behavior of both apo and metal
bound forms was analyzed. Addition of Ag(I) or Hg(II) ions
yielded very similar NMR spectra (Fig. 5S, ESI†), suggesting
similar coordination features for both metals. However, the
spectra of the silver complex were broader than the mercury
ones, such that successive analyses were carried out on Hg(II)
systems only.
Hg(II) titration experiments were performed to determine
the metal binding stoichiometry, up to 1.8. Hg(II) equivalents
were added to Bri2-23 solutions. Hg(II) additions up to 0.9
equivalents resulted in the change of NMR parameters of
selected proton and carbon NMR resonances, on the contrary
higher metal concentrations did not significantly further aﬀect
the spectra, except for increased line broadening of NMR
signals, probably due to the presence of intermolecular species
or soluble aggregates. The addition of 0.5 Hg(II) equivalents
causes the reduction of NMR resonances belonging to the apo
form with the simultaneous appearance of new peaks corres-
ponding to the metal-bound form (Fig. 8A), indicating the
Table 3 Stability constants for the Hg(II) complexes of Bri2-23 at a Hg(II)/
Bri2-23 ratio 1 : 2; T = 298.2 K and I = 0.1 M in NaCl; cBri2-23 = 1  103,
cHg(II) = 5  104
Speciesa log b logK logK*b
HgH6L 55.10(2) 0.73
HgH5L 52.09(1) 3.01 1.22
HgH4L 48.65(1) 3.44 1.91
HgH3L 44.01(1) 4.64 2.03
HgH2L 37.72
c 6.29 2.10
HgHL 29.54(1) 8.18 1.49
HgL 18.59(2) 10.95 0.59
a L indicates the Bri2-23 peptide as a ligand. b logK* = log b(CuHjL) 
log b(HnL) (where the index j corresponds to the number of the protons
in the coordinated ligand to the metal ion and n corresponds to the
number of protons coordinated to the ligand). c Calculated in the
ternary system.
Fig. 6 Species distribution diagram for Hg(II) complexes of the Bri2-23
peptide at a 1 : 2 Hg/Bri2-23 ratio; T = 298.2 K and I = 0.1 M in NaCl;
cBri2-23 = 1  103, cHg(II) = 5  104.
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occurrence of a slow exchange regime (respect to the NMR time
scale) between the free and bound states. The presence of both
apo and metal bound signals observed in that condition strongly
indicate that 1 : 1 complexes, rather than bis-complexes, are
formed. Further addition of Hg(II) results in (i) the complete
disappearance of the NMR resonances of the apo Bri2-23 and (ii)
an increase of the intensity of the peaks corresponding to the
metal complex (Fig. 8B). Furthermore, the correlations observed
upon the addition of 0.5 metal equivalents are well superim-
posed to those corresponding to either the free or metal bound
Bri2-23 (Fig. 6S, ESI†). In addition, the NMR spectra revealed the
occurrence of two Hg(II) bound forms in slow exchange with
respect to the NMR time scale. The two forms (hereafter called
form X and Y) exhibited clear and diverse NMR signals for
residues 9–21, while showed similar chemical shifts for the first
8 residues. From the evaluation of the relative intensities of the
NMR signals belonging to the two bound forms, the form X was
found to be more abundant than the other. The full 1H assign-
ments of Bri2-23 and the two Hg(II) bound forms (X and Y) are
reported in Tables 2S–4S (ESI†).
After the complete assignment of the NMR spectra of the
apo and Hg(II) bound Bri2-23 forms, the Chemical Shift Index
(CSI) and the Chemical Shift Variation induced by the metal ion
for the most abundant species (form X) was calculated. The CSI,
calculated on the chemical shift of the Ha protons, is reported
in Fig. 9. The results obtained for the apo peptide confirm the
random coil nature of Bri2-23, as previously detected from CD
analysis. On the other hand the CSI obtained for the metal
bound form demonstrates a behavior typical of a b strand
structured peptide, especially for the regions from Asn-4 to
Arg-9 and from Val-17 to Cys-22. Similar results were obtained
by the analysis of the chemical shift variation induced by Hg(II)
on NH and Ha protons (Fig. 10). Both metal bound forms show
large chemical shift variations, especially in the regions from
4 to 8 and from 16 to 22. In order to better determine the metal
binding donor atoms, the Hg(II) induced chemical shift varia-
tions on all of side-chain protons were calculated as well
(Fig. 10). The protons exhibiting the largest changes belong
to Hb of both Cys-5 and Cys-22, strongly supporting the metal
coordination to thiolate groups.
The analysis of 2D 1H–1H NOESY spectra was also performed
in order to determine the three dimensional structure of the
Bri2-23–Hg(II) complex. 70 NOEs were thus converted to pro-
ton–proton distance constraints to be used for structure calcu-
lation by using the DYANA program. However no clear cut
arrangement of the peptide was obtained from those calcula-
tions (bb-RMSD: 4.38  0.94 Å, and an average target function
of 1.08  0.023).
Molecular dynamics simulations
The structural propensity of the Bri2-23–Hg(II) complex was inves-
tigated by Molecular Dynamics Simulations (MD) performed on
seven random structures selected from the thirty ones generated
from DYANA calculation (Fig. 7S, ESI†). Combination of experi-
mental and theoretical techniques has been previously applied to
investigate metal binding to amyloidogenic model peptides.61–64
For each of the seven structures shown, a 100 ns of MD
simulation was performed using the simulation program
GROMACS.31 Contrary to the NMR analysis, we decided to
run MD by considering Cu(I) instead of Hg(II) or Ag(I) as the
metal bound ion. This choice was mainly due to the fact that
Cu(I) is the real metal of interest and that Hg(II) and Ag(I) were
just used as probes for Cu(I) in the spectroscopic analysis.
Among the seven analyzed structures only five easily reached
bb-RMSD convergence after 100 ns (Fig. 11, structures A, B, C,
D and G). The stability of each simulated systems was con-
trolled also through the output pdb files, where backbone
overlap occurred in the last 20 ns confirming the secondary
structure stability (Fig. 11). For structures E and F, after 100 ns
of simulation, bb-RMSD did not converge. This can happen
when (i) the system attains a random coil secondary structure,
so the bb will not be stable at all, or (ii) the major part of the
bb remain stable over time while the C- and N-terminus
(which could be the random part of the sequence) have a high
mobility. To monitor this behavior the fluctuation of single
residues over time was calculated for structures E and F.
As shown in Fig. 8S (ESI†), we found that the N- and
C-termini are much more unstable than the central part of
the sequence (especially for structure F). For these reasons we
decided to include in our analysis also the results obtained
from structures F and E.
Ribbon representations are shown in Fig. 11. Structures
A, B, C, E and G present a well defined conformation, composed
by a short N- and C-termini random part, followed by a short
b-sheet (parallel or anti-parallel) and a central domain consti-
tuted by turn and bend elements. In contrast, structures D and
F do not possess an intrinsic b-sheet frame, and they just show
the features of a simple but well organized conformation
characterized by a bend, turn and b-bridge secondary structure.
From a statistical point of view, 5 of the 7 analyzed struc-
tures show a well defined b sheet arrangement, demonstrating
the high propensity of the Cu(I) bound peptide to adopt a
partial b sheet secondary structure, confirming the analysis of
the CD, ThT and NMR experimental data (Sections 1–3). The
obtained data support the existence of a b sheet region located
Table 4 Schematic representation of amino acid residues involved in b
sheet formation
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in the proximity of the metal binding site (Cys-5 and Cys-22).
The amino acids involved in the b sheet formation are not
unequivocally determined (see Table 4) suggesting the dynamic
nature of the system. Interestingly, the distance between the
two sheets is constant, despite the structured part starts at Ser-3
or at Phe-6.
Discussion
Knowledge of metal binding properties of Bri2 and the pro-
ducts of its proteolytic cleavage is limited to one report related
to metallochemistry of ABri, the amyloidogenic product of
the furin cleaved homologue of Bri2.20 There are no similar
studies for the wild type peptide (Bri2-23) that, contrary to its
pathogenic homologue, does not aggregate and even eﬀectively
inhibits Ab aggregation.
Our major interest was to examine the interaction of Bri2-23
with soft metal ions, by using Hg(II) and Ag(I) as Cu(I) probes, to
assess the impact of metal sequestration on peptide structure
and metal binding aﬃnity under conditions where aggregation
is disfavored. Hg(II) is known for very high aﬃnity for thiolate
containing ligands. Hg(II) binding to low molecular weight
compounds like cysteine, penicillamine, and glutathione typi-
cally yields extremely stable complex species. On the other
hand, the selectivity of metal ion binding to peptides contain-
ing two or more cysteinyl residues is strongly dependent on the
distance between the thiolates involved in metal ion sequestra-
tion,65 over and above their conformational orientation.57,66
Design of peptides that predispose binding thiolates into metal
preferred orientation yielded exceptionally stable complex species
able to compete with low molecular weight compounds in Hg(II)
sequestration.57
Fig. 7 Fourier transformed 199mHg PAC data for Bri2-23 in 50 mM
phosphate buﬀer, pH 3.0 or 7.4 with the addition of sucrose (55%);
cHg(II) = 1  104 M, Hg(II)/Bri2-23 ratio 1 : 1 or 1 : 2. Blue: fourier trans-
formed experimental data; black: fit with the parameters presented in
Table 1S (ESI†). Vertical blue lines are added to aid the eye, at the
frequencies recorded at pH 3.0 with 2 : 1 Bri2-23 to Hg(II) stoichiometry,
reflecting a typical HgS2 coordination geometry.
Fig. 8 2D 1H–1H TOCSY spectra (NH-Ha region) of Bri2-23 0.5 mM in H2O :D2O 90 : 10 at 298K and pH 3.0 in the presence of (A) 0.5 equivalents of
Hg(II) ions; (B) 0.7 equivalents of Hg(II) ions.
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As demonstrated by the CD and NMR analyses apo Bri2 23
preferentially adopts random conformation, which do not favor
the intramolecular mercury(II) binding to Cys-5 and Cys-22,
separated by 16 amino acid residues. Nonetheless, Bri2-23 has
the ability to form Hg(II) mononuclear intramolecular species
with a HgS2 coordination geometry, as indicated by the analysis
of ESI MS data (Fig. 3). The isotopic profile of the detectable
species perfectly matches the simulated mononuclear intra-
molecular HgBri2-23 complex. Furthermore, although PAC
spectroscopy does not discriminate between the intra- or
inter-molecular metal site, it confirms the occurrence of HgS2
coordination geometry in solution at low pH (Fig. 7). Similarly,
the large chemical shift changes observed for Cys-5, Cys-22 and
residues nearby, indicates that these residues are coordinated
to Hg(II) in the predominant metal complex (Fig. 10). Interest-
ingly, nearly exclusive intramolecular binding is observed at
metal ion concentrations not exceeding 0.5 molar equivalents
with respect to the peptide, as reflected by the NMR and
potentiometric analysis (Fig. 6 and 8). NMR analysis also
revealed the presence of two metal-bound species with form
(X) still predominant in the equilibrium. Relatively low concen-
tration of minor species (Y) does not allow for its comprehen-
sive structural analysis.
As indicated by the large broadening of NMR signals and by
the ITC experiments, further increase of M :L ratios results in the
evolution of metal-bridged oligomeric species (e.g.Hgm(BRI2 23)n)
that may coexist in solution with HgBri2-23 macrochelates. This
behavior epitomizes previously detected pH dependent scram-
bling of ABri.67
Our titration experiments indicate that Hg(II) interact with
Bri2-23 in a concentration dependent manner, yielding primar-
ily a mixture of intramolecular macrochelate and structurally
undefined species that with metal concentration exceeding
0.7 Hg(II) equivalents are converted into polymeric species of
unknown structure and stoichiometry. Aggregates giving
response in ThT assays are formed, indicating that the presence
Fig. 9 Chemical Shift Index of Bri2-23 apo form (left panel) and of the most abundant Hg(II)–Bri2-23 complex X (right panel).
Fig. 10 Chemical shift variation induced by Hg(II) on Bri2-23 protons.
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of 0.7 Hg(II) or Ag(I) equivalents does lead to aggregation
(Fig. 2).
The three dimensional structure of the mononuclear Bri2-23
complex was unapproachable directly from NMR data analysis.
However, NMR provided reliable constraints to molecular
dynamics analysis. Nearly all MD trajectories present a predo-
minantly b sheet arrangement of peptide structure upon metal
binding in contrast to a completely random structure of the free
peptide (Fig. 11). As indicated in Table 4, the residues involved
in the b-sheet structure are not well defined. This behavior is
consistent with a relative flexibility of the b-sheet rearrange-
ment and it is in agreement with the lack of precise NOE
constraints unequivocally leading to the NMR structure of the
metal complex. However, as supported by the chemical shift
analysis (Fig. 9) and by the MD data (Fig. 11), metal ion binding
has a critical impact on molecular architecture of the peptide
and enforces its refolding to yield species of predominant b
pleated sheet conformation, hence more prone to aggregation.
Although these species are not exactly the same in terms of
proposed molecular architecture of the peptide backbone, most
of them resemble either parallel or antiparallel b-sheet rich
structures. The suggested conformational shift is additionally
supported by changes in the far-UV profile of CD spectra
demonstrating transition towards b-sheet arrangement of the
peptide backbone (Fig. 4).
Formation of oligomeric species observed at a higher metal
concentration may either proceed through subsequent Hg(II)
and peptide incorporation that yields an expanded metal
bridged precipitate or alternatively represents the required core
for Bri2-23 aggregation. The time dependence and molecular
mechanism of aggregation remains to be elucidated. As a
consequence, metal ion sequestration may eradicate a key
attribute of Bri2-23, its Ab aggregation inhibitory activity and/
or even convert the peptide into an aggregation promoter.
Fig. 11 Backbone RMSD, secondary structure evolutions as a function of time (upper panel) and the snapshots from the last part of the MD trajectories
of Hg(II)-Bri2-23 molecules (lower panel).
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